Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsHideho Okada, Walter Storkus, Junichi Eguchi, Hidemitsu Sato
Life of this patent
Estimating the term…
Abstract
The invention provides a peptide derived from the interleukin-13 receptor α2, which serves as a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope. The invention can be used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use. In addition, the invention provides the use of a peptide derived from the Eph family of tyrosine kinase receptors which can be also used as a vaccine for glioma and can be formulated into compositions for medical or veterinary use.
Claims36
An isolated peptide comprising an amino acid sequence comprising a substitution mutant variant of WLPFGFILI (SEQ ID NO:1), wherein at least one of the amino acid residues in SEQ ID NO:1 is substituted with an amino acid other than the indicated residue.
An isolated peptide comprising a sequence of amino acid residues comprising WLPFGFILV (SEQ ID NO:2).
An isolated peptide comprising a sequence of amino acid residues comprising ALPFGFILV (SEQ ID NO:3).
An isolated peptide comprising a sequence of amino acid residues comprising ELPFGFILV (SEQ ID NO:4).
The use of a peptide having the sequence TLADFDPRFV (SEQ ID NO:6) to prepare a medicament useful as a vaccine against glioma.
A method of vaccinating a patient against glioma, comprising introducing into the patient a peptide having the sequence TLADFDPRFV (SEQ ID NO:6) under conditions sufficient for said patient to develop a cytoxic T-cell lymphocyte (CTL) response.
The use of a composition comprising a peptide having the sequence TLADFDPRFV (SEQ ID NO:6) and a physiologically acceptable carrier to prepare a medicament useful as a vaccine against glioma.
A method of vaccinating a patient against glioma, comprising introducing into the patient a composition comprising a peptide having the sequence TLADFDPRFV (SEQ ID NO:6) and a physiologically acceptable carrier under conditions sufficient for said patient to develop a cytoxic T-cell lymphocyte (CTL) response.
Dependencies are inferred from the claim text.